AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$IMRX

Immuneering Corp

Price · $IMRXvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $IMRX in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $IMRX in the last 30 days.

Top stories · $IMRXMore →
FEB 3·Stock TitanHigh

IMRX Stock Price, News & Analysis

Immuneering Corporation (IMRX) is a clinical-stage oncology company listed on Nasdaq, focused on developing Deep Cyclic Inhibitors (DCIs) for cancer treatment. Its lead product candidate, atebimetinib, targets MAPK pathway-driven tumors, including pancreatic cancer and NSCLC, and is currently in Phase 1/2a clinical trials with a planned Phase 3 registrational trial. The company has secured patent exclusivity for atebimetinib until 2042 and actively engages in collaborations and regulatory discussions with the FDA and EMA to advance its pipeline.

DEC 12·Stock Titan

IMRX - Immuneering Corp Latest Stock News & Market Updates

This page provides investors with the latest news and updates on Immuneering Corporation (IMRX), a clinical-stage biopharmaceutical company focused on oncology and neurology therapeutics. The content covers scientific progress, strategic partnerships, regulatory developments, and financial updates, with a particular focus on their lead drug candidate, atebimetinib, for pancreatic cancer. Recent news highlights include clinical trial results, financial reporting, and leadership appointments.

News on $IMRX

All news →